Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival.
Biomarkers, Tumor
/ metabolism
Black People
/ genetics
Breast Neoplasms
/ ethnology
Estrogen Receptor alpha
/ metabolism
Female
GATA3 Transcription Factor
/ metabolism
Gene Expression Regulation, Neoplastic
Health Status Disparities
Hepatocyte Nuclear Factor 3-alpha
/ metabolism
Humans
Immunohistochemistry
/ methods
Middle Aged
Survival Rate
United States
White People
/ genetics
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
19
03
2019
revised:
10
07
2019
accepted:
03
01
2020
pubmed:
9
1
2020
medline:
28
1
2021
entrez:
9
1
2020
Statut:
ppublish
Résumé
Compared with their European American (EA) counterparts, African American (AA) women are more likely to die from breast cancer in the United States. This disparity is greatest in hormone receptor-positive subtypes. Here we uncover biological factors underlying this disparity by comparing functional expression and prognostic significance of master transcriptional regulators of luminal differentiation. Data and biospecimens from 262 AA and 293 EA patients diagnosed with breast cancer from 2001 to 2010 at a major medical center were analyzed by IHC for functional biomarkers of luminal differentiation, including estrogen receptor ( Univariate or multivariate HRs for overall survival, estimated from digital IHC scoring of nuclear antigen, show distinct differences in the magnitude and significance of these biomarkers to predict survival based on race: Even within clinically homogeneous tumor groups, regulatory networks that drive mammary luminal differentiation reveal race-specific differences in their association with clinical outcome. Understanding these biomarkers and their downstream regulons will elucidate the intrinsic mechanisms that drive racial disparities in breast cancer survival.
Identifiants
pubmed: 31911546
pii: 1078-0432.CCR-19-0875
doi: 10.1158/1078-0432.CCR-19-0875
pmc: PMC8051554
mid: NIHMS1627062
doi:
Substances chimiques
Biomarkers, Tumor
0
ESR1 protein, human
0
Estrogen Receptor alpha
0
FOXA1 protein, human
0
GATA3 Transcription Factor
0
GATA3 protein, human
0
Hepatocyte Nuclear Factor 3-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1905-1914Subventions
Organisme : NCI NIH HHS
ID : P30 CA013696
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA MD000016
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Genome Res. 2013 Jan;23(1):12-22
pubmed: 23172872
Clin Cancer Res. 2010 Dec 15;16(24):6100-10
pubmed: 21169259
Curr Opin Genet Dev. 2016 Apr;37:76-81
pubmed: 26826681
Breast Cancer Res. 2018 Feb 06;20(1):12
pubmed: 29409530
Bioinformatics. 2006 Jun 15;22(12):1540-2
pubmed: 16595560
J Natl Cancer Inst. 2009 Jul 15;101(14):984-92
pubmed: 19584328
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28859290
MMWR Morb Mortal Wkly Rep. 2018 Jun 01;67(21):614
pubmed: 29851940
Methods Mol Biol. 2017;1526:99-117
pubmed: 27896738
Expert Rev Mol Med. 2009 Mar 05;11:e8
pubmed: 19261198
Am J Clin Pathol. 2017 Aug 1;148(2):108-118
pubmed: 28898983
Stem Cells. 2015 Feb;33(2):367-77
pubmed: 25336442
Nat Rev Cancer. 2009 Sep;9(9):631-43
pubmed: 19701242
Nat Rev Cancer. 2011 Jun 16;11(7):523-32
pubmed: 21677677
J Natl Cancer Inst. 2012 Mar 7;104(5):406-14
pubmed: 22250182
J Clin Oncol. 2015 Mar 20;33(9):1053-9
pubmed: 25691670
Breast Cancer Res Treat. 2017 Nov;166(2):559-568
pubmed: 28756535
Genome Biol. 2013 Feb 14;14(2):R12
pubmed: 23409703
Nature. 2012 Jan 04;481(7381):389-93
pubmed: 22217937
Cell. 2008 Mar 21;132(6):958-70
pubmed: 18358809
Breast Cancer Res Treat. 2015 Apr;150(3):667-74
pubmed: 25814053
Nat Commun. 2018 Oct 16;9(1):4181
pubmed: 30327465
JAMA Oncol. 2017 Dec 1;3(12):1654-1662
pubmed: 28472234
CA Cancer J Clin. 2016 Jul;66(4):290-308
pubmed: 26910411
JAMA. 2013 Jul 24;310(4):389-97
pubmed: 23917289
Nat Biotechnol. 2012 Feb 12;30(3):253-60
pubmed: 22327324
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Breast Cancer Res Treat. 2009 Jan;113(2):357-70
pubmed: 18324472
Crit Rev Diagn Imaging. 1989;29(3):307-35
pubmed: 2667567
J Biol Chem. 2010 Apr 30;285(18):14042-51
pubmed: 20189993
Genome Biol. 2016 Feb 27;17:36
pubmed: 26922637
Nat Genet. 2011 Jan;43(1):27-33
pubmed: 21151129
Nat Rev Cancer. 2007 Sep;7(9):713-22
pubmed: 17721435
CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42
pubmed: 26513636
J Clin Oncol. 2018 Jan 1;36(1):14-24
pubmed: 29035645
Mol Cell Endocrinol. 2004 Apr 30;219(1-2):1-7
pubmed: 15149721
J Clin Oncol. 2015 Jul 10;33(20):2254-61
pubmed: 25964252
J Natl Cancer Inst. 2009 Jul 15;101(14):993-1000
pubmed: 19584327
J Clin Oncol. 2009 May 1;27(13):2157-62
pubmed: 19307504
Nat Genet. 2012 Nov;44(11):1191-8
pubmed: 23001124
Genet Med. 2017 Jul;19(7):787-795
pubmed: 28125075
Science. 2002 May 31;296(5573):1642-4
pubmed: 12040178
JAMA Surg. 2017 May 1;152(5):485-493
pubmed: 28355428
Cell Rep. 2017 Aug 15;20(7):1623-1640
pubmed: 28813674
J Clin Oncol. 2018 Mar 1;36(7):652-658
pubmed: 29341832
Cold Spring Harb Perspect Biol. 2011 Feb 01;3(2):
pubmed: 21047916
Oncogene. 2013 Jan 31;32(5):554-63
pubmed: 22391567
Methods Enzymol. 2006;410:400-15
pubmed: 16938563
J Clin Oncol. 2015 Nov 1;33(31):3621-7
pubmed: 26371147
J Clin Oncol. 2006 Mar 20;24(9):1342-9
pubmed: 16549828
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Oncogene. 2015 Sep 24;34(39):5012-24
pubmed: 25531315
Nat Commun. 2018 Mar 13;9(1):1059
pubmed: 29535312